PIK3CA testing and treatment patterns in hormone receptor–positive, HER2-negative metastatic breast cancer in a United States health network

Introduction Targeted treatments are approved and in development for PIK3CA -mutated, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer. Current clinical guidelines recommend biomarker testing. This retrospective cohort study characterized PIK3CA mutation testing and treatment patterns for HR+, HER2– metastatic breast cancer (mBC) in real-world clinical practice. Methods A nationwide electronic health record–derived de-identified database was used to select patients diagnosed with HR+, HER2– mBC from January 1, 2011, to July 31, 2025. Patients had ≥2 documented visits after January 1, 2011, and structured clinical activity or visits ≤90 days from their metastatic diagnosis date. Results Among 23,044 patients, 8824 had ≥1 PIK3CA test. Test rates increased from 2011 to 2025 for patients starting first-, second-, or third-line treatment. In 2025, the testing rates any time prior to first-, second-, and third-line start dates were 20.2%, 61.6%, and 75.1%, respectively. Overall median time from mBC diagnosis to PIK3CA testing date was 4.8 months (range: 14.3 months [2019] to 2.3 months [2025]). Overall, 91.0% of PIK3CA tests were next-generation sequencing and 61.1% used tumor tissue. From 2019 onwards, 30.4% of patients with a positive test result received a PI3K or AKT inhibitor. Conclusion While PIK3CA mutation testing in patients with HR+, HER2– mBC has increased over time and shifted to earlier lines of therapy, overall rates of testing and subsequent use of targeted therapies remain low. This highlights potential gaps in both biomarker identification and uptake of PI3K or AKT inhibitors. Additionally, optimized processes are needed to reduce the time from diagnosis to testing. Specifically, prompt evaluation of patients whose disease recurs during or within 12 months of completing adjuvant endocrine therapy presents a critical opportunity to administer a biomarker-directed regimen (i.e., a combination of PI3K inhibitor, cyclin-dependent kinase 4/6 inhibitor, and endocrine therapy) with a demonstrated survival benefit.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1953840
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PIK3CA testing and treatment patterns in hormone receptor–positive, HER2-negative metastatic breast cancer in a United States health network

Peter M. Lambert, Reva Kakkar Basho, Emma Behan, Anna Barulich et al.
2 links
Frontiers in Oncology
Advanced Breast Cancer Therapies
article

PIK3CA testing and treatment patterns in hormone receptor–positive, HER2-negative metastatic breast cancer in a United States health network

Peter M. Lambert, Reva Kakkar Basho, Emma Behan, Anna Barulich, Eunice Kim, Preet Kaur Dhillon
article en

Abstract

Introduction Targeted treatments are approved and in development for PIK3CA -mutated, hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer. Current clinical guidelines recommend biomarker testing. This retrospective cohort study characterized PIK3CA mutation testing and treatment patterns for HR+, HER2– metastatic breast cancer (mBC) in real-world clinical practice. Methods A nationwide electronic health record–derived de-identified database was used to select patients diagnosed with HR+, HER2– mBC from January 1, 2011, to July 31, 2025. Patients had ≥2 documented visits after January 1, 2011, and structured clinical activity or visits ≤90 days from their metastatic diagnosis date. Results Among 23,044 patients, 8824 had ≥1 PIK3CA test. Test rates increased from 2011 to 2025 for patients starting first-, second-, or third-line treatment. In 2025, the testing rates any time prior to first-, second-, and third-line start dates were 20.2%, 61.6%, and 75.1%, respectively. Overall median time from mBC diagnosis to PIK3CA testing date was 4.8 months (range: 14.3 months [2019] to 2.3 months [2025]). Overall, 91.0% of PIK3CA tests were next-generation sequencing and 61.1% used tumor tissue. From 2019 onwards, 30.4% of patients with a positive test result received a PI3K or AKT inhibitor. Conclusion While PIK3CA mutation testing in patients with HR+, HER2– mBC has increased over time and shifted to earlier lines of therapy, overall rates of testing and subsequent use of targeted therapies remain low. This highlights potential gaps in both biomarker identification and uptake of PI3K or AKT inhibitors. Additionally, optimized processes are needed to reduce the time from diagnosis to testing. Specifically, prompt evaluation of patients whose disease recurs during or within 12 months of completing adjuvant endocrine therapy presents a critical opportunity to administer a biomarker-directed regimen (i.e., a combination of PI3K inhibitor, cyclin-dependent kinase 4/6 inhibitor, and endocrine therapy) with a demonstrated survival benefit.

Frontiers in OncologyVol. 16
Genentech (US), Ellison Medical Institute (US)
Genentech
Good health and well-being
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon